Richard E Deichmann1, Carl J Lavie2, Timothy Asher3, James J DiNicolantonio4, James H O'Keefe4, Paul D Thompson5. 1. Department of Internal Medicine, Ochsner Clinic Foundation, New Orleans, LA ; The University of Queensland School of Medicine, Ochsner Clinical School, New Orleans, LA. 2. The University of Queensland School of Medicine, Ochsner Clinical School, New Orleans, LA ; Department of Cardiovascular Diseases, John Ochsner Heart & Vascular Institute, Ochsner Clinic Foundation, New Orleans, LA. 3. The University of Queensland School of Medicine, Ochsner Clinical School, New Orleans, LA. 4. Department of Cardiology, Mid America Heart Institute, Saint Luke's Health System, Kansas City, MO. 5. Department of Cardiology, Hartford Hospital, Hartford, CT.
Abstract
BACKGROUND: Broad indications for the use of statin medications are resulting in more patients using these therapies. Simultaneously, healthcare professionals are strongly advocating recommendations to increase exercise training (ET) as a means of decreasing cardiovascular disease (CVD) risk and improving other parameters of fitness. METHODS: We review the literature to explore mechanisms that may increase the risk of statin/ET interactions, examine the benefits and risks of combining ET and statin use, and offer strategies to minimize the hazards of this combination therapy. RESULTS: The combined use of statins and ET can result in health gains and decreased CVD risk; however, multiple factors may increase the risk of adverse events. Some of the events that have been reported with the combination of statins and ET include decreased athletic performance, muscle injury, myalgia, joint problems, decreased muscle strength, and fatigue. The type of statin, the dose, drug interactions, genetic variants, coenzyme Q10 deficiency, vitamin D deficiency, and underlying muscle diseases are among the factors that may predispose patients to intolerance of this combined therapy. CONCLUSION: Effective strategies exist to help patients who may be intolerant of combined statin therapy and ET so they may benefit from this proven therapy. Careful attention to identifying high-risk groups and strategies to prevent or treat side effects that may occur should be employed.
BACKGROUND: Broad indications for the use of statin medications are resulting in more patients using these therapies. Simultaneously, healthcare professionals are strongly advocating recommendations to increase exercise training (ET) as a means of decreasing cardiovascular disease (CVD) risk and improving other parameters of fitness. METHODS: We review the literature to explore mechanisms that may increase the risk of statin/ET interactions, examine the benefits and risks of combining ET and statin use, and offer strategies to minimize the hazards of this combination therapy. RESULTS: The combined use of statins and ET can result in health gains and decreased CVD risk; however, multiple factors may increase the risk of adverse events. Some of the events that have been reported with the combination of statins and ET include decreased athletic performance, muscle injury, myalgia, joint problems, decreased muscle strength, and fatigue. The type of statin, the dose, drug interactions, genetic variants, coenzyme Q10 deficiency, vitamin D deficiency, and underlying muscle diseases are among the factors that may predispose patients to intolerance of this combined therapy. CONCLUSION: Effective strategies exist to help patients who may be intolerant of combined statin therapy and ET so they may benefit from this proven therapy. Careful attention to identifying high-risk groups and strategies to prevent or treat side effects that may occur should be employed.
Authors: Gualberto Ruaño; Andreas Windemuth; Alan H B Wu; John P Kane; Mary J Malloy; Clive R Pullinger; Mohan Kocherla; Kali Bogaard; Bruce R Gordon; Theodore R Holford; Ankur Gupta; Richard L Seip; Paul D Thompson Journal: Atherosclerosis Date: 2011-07-20 Impact factor: 5.162
Authors: Luis Carlos López; Markus Schuelke; Catarina M Quinzii; Tomotake Kanki; Richard J T Rodenburg; Ali Naini; Salvatore Dimauro; Michio Hirano Journal: Am J Hum Genet Date: 2006-10-27 Impact factor: 11.025
Authors: B A Masters; M J Palmoski; O P Flint; R E Gregg; D Wang-Iverson; S K Durham Journal: Toxicol Appl Pharmacol Date: 1995-03 Impact factor: 4.219
Authors: David J Graham; Judy A Staffa; Deborah Shatin; Susan E Andrade; Stephanie D Schech; Lois La Grenade; Jerry H Gurwitz; K Arnold Chan; Michael J Goodman; Richard Platt Journal: JAMA Date: 2004-11-22 Impact factor: 56.272
Authors: Wilson Chen; Heather M Ochs-Balcom; Changxing Ma; Paul J Isackson; Georgirene D Vladutiu; Jasmine A Luzum Journal: Future Cardiol Date: 2022-03-17
Authors: Irena A Rebalka; Andrew W Cao; Linda L May; Mark A Tarnopolsky; Thomas J Hawke Journal: Am J Physiol Cell Physiol Date: 2019-09-11 Impact factor: 4.249